Understanding how immune activation changes the environment around pancreatic cancer cells
Dissecting how activated immunity reshapes the stromal TME of pancreatic ductal adenocarcinoma
['FUNDING_FELLOWSHIP'] · WASHINGTON UNIVERSITY · NIH-11067055
This study is looking at how the surroundings of pancreatic cancer cells affect the immune system and aims to find ways to make current treatments work better for patients by understanding the role of certain cells in that environment.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11067055 on ClinicalTrials.gov |
What this research studies
This research investigates the role of the tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) and how activating the immune system can reshape this environment. The study focuses on different types of cancer-associated fibroblasts and their impact on anti-tumor immunity. By examining how these cells interact with immune responses, the research aims to uncover why current immunotherapies are ineffective for PDAC and how they might be improved. Patients may benefit from insights that could lead to more effective treatments in the future.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who may be eligible for immunotherapy.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective immunotherapies for pancreatic cancer, improving survival rates for patients.
How similar studies have performed: While immunotherapy has shown success in other cancer types, the specific approach being investigated for pancreatic cancer is novel and has not yet been proven effective.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SELLS, BLAKE — WASHINGTON UNIVERSITY
- Study coordinator: SELLS, BLAKE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: cancer immunity, cancer immunology, cancer microenvironment